Pancreatic Cancer Analysis Points to Possibility of Targeting VISTA Immune Checkpoint

NEW YORK (GenomeWeb) – New research suggests that an immune checkpoint protein called VISTA may serve as a target for future immunotherapy development in pancreatic ductal adenocarcinoma (PDAC), which is known for its poor outcomes and resistance to existing immune checkpoint therapies that target proteins such as PD-1 or CTLA4.